Your Fat Has a Storage Limit

Episode Overview

• Dr. Jordan Feigenbaum (host of the Barbell Medicine Podcast, author of the upcoming book Signal, and founder of Barbell Medicine coaching) investigates whether subcutaneous or visceral body fat is the primary driver of metabolic diseases like type 2 diabetes, or if disease is actually caused by ectopic fat—fuel overflowing into organs like the liver, muscle, and pancreas.
• The narrative traces decades of physiological research, starting with surgical fat-removal studies (liposuction and omentectomy) that failed to improve metabolic health, moving through metabolic ward diet trials, and examining rare conditions like congenital generalized lipodystrophy and paradoxical weight-gain drugs like pioglitazone.
• By connecting these clinical puzzles, the episode builds the case for the "Personal Fat Threshold"—the concept that metabolic disease occurs when an individual exceeds their genetically predetermined safe fat storage capacity, regardless of their scale weight or BMI.
• The episode concludes with a practical breakdown of the 2025 Lancet Commission guidelines on clinical obesity and evaluates specific diagnostic tools (waist-to-height ratio, TyG index, FIB-4, and elastography) for catching hidden metabolic dysfunction and liver scarring in both obese and normal-weight individuals.

Key Concepts

• Surgical Fat Removal vs. Normal Weight Loss: In a 2004 study by Dr. Samuel Klein, removing ~10 kg of subcutaneous abdominal fat (a quarter to nearly half of their subcutaneous abdominal fat) from 15 women (8 with normal blood sugar, 7 with type 2 diabetes) yielded zero improvements in insulin sensitivity, blood pressure, blood sugar, cholesterol, or inflammation at 12 weeks and 4 years post-op. Similarly, a 2010 omentectomy study (Fabbrini et al.) showed that surgically removing the omentum (visceral fat apron draining into the portal vein) provided no added benefit to gastric bypass patients (22 patients randomized) and zero improvement in insulin sensitivity or medication use when performed alone on 7 type 2 diabetics held at steady weight for 3 months. Normal weight loss works not merely by removing fat mass, but by shrinking existing fat cells, slowing fatty acid leakage, and pulling fat out of the muscles, liver, and visceral depot simultaneously.
• Subcutaneous vs. Visceral Fat Dynamics: Subcutaneous fat is pinchable fat under the skin, whereas visceral fat sits behind the abdominal wall around organs. Visceral fat is dangerous because it produces proteins that impair blood clot breakdown, feeds blood-pressure-raising systems, and underproduces adiponectin (a protective hormone). However, visceral fat accumulation is a downstream symptom showing that the primary subcutaneous storage system is already overwhelmed.
• Insulin Resistance and the Refutation of the Carbohydrate-Insulin Model: Normally, post-meal insulin signals muscle, liver, and fat cells to clear blood fuel (glucose, fatty acids, amino acids) and stops fat cells from releasing stored fat—a cycle resolving in ~2 hours. When tissues become insulin resistant, the pancreas compensates by over-secreting insulin, keeping blood sugar normal on lab tests for 10 to 15 years before failing and triggering a type 2 diabetes diagnosis. However, insulin itself is not the primary cause of fat gain: Dr. Kevin Hall's metabolic ward study showed that cutting dietary fat by the exact same calorie amount as carbohydrates led to slightly more body fat loss, and a 1-year randomized trial of 600 people on low-fat vs. low-carb diets produced identical weight loss even among the highest insulin secretors.
• The Personal Fat Threshold and Ectopic Fat: Subcutaneous fat acts as a "smart garage" (an endocrine organ communicating with the brain, liver, and muscle). Radioactive carbon-14 dating of fat cell DNA (using atmospheric spikes from 1950s–1960s nuclear testing) shows fat cell numbers are mostly set by late adolescence, holding steady for life with ~10% (1 in 10) replaced annually. When you exceed your genetically/developmentally set garage size—your Personal Fat Threshold—fuel overflows as ectopic fat into the liver, pancreas, kidneys, muscles, and heart space, causing those stuffed cells to ignore insulin.
• The True Source of Fatty Liver: A 2005 study using chemically tagged food and liver biopsies in 9 people with fatty livers revealed where intrahepatic fat actually originates: only ~15% came from dietary fat (dinner), ~25% was synthesized by the liver from carbohydrates, and nearly 60% leaked out of the patients' own insulin-resistant fat tissue into the bloodstream.
• Lipodystrophy and Leptin Replacement: Congenital generalized lipodystrophy (~1 in 10 million prevalence; a couple hundred cases in literature) leaves patients born with almost zero fat tissue, appearing muscular with insatiable childhood appetites, acanthosis nigricans, and enlarged fatty livers. In an untreated cohort of 43 patients, 80% (8 in 10) had organ damage (mostly liver), though fewer than half had pre-diabetic blood sugar early on. In a 2002 Yale/NIH study of 3 lipodystrophy patients vs. 6 matched controls (highlighted by Dr. Feigenbaum for the depth of its 4-to-6-hour, 2-staff hyperinsulinemic-euglycemic clamp and scan measurements rather than its tiny sample size), an index 17-year-old female had 0% subcutaneous fat, milky fat-filled blood plasma, and a 48% fat liver (vs. <1% in healthy women). Three months of daily leptin injections cut food intake roughly in half (in the 1 patient measured), dropped liver fat by >80%, cut muscle fat by ~1/3, multiplied insulin responsiveness several-fold, and got all 3 off diabetes medications without changing body weight or fat mass. Conversely, giving leptin to people with ordinary obesity does almost nothing because they already have high leptin (which defends against starvation, not overeating).
• Expanding the Garage via Pioglitazone: Pioglitazone is a diabetes medication that signals subcutaneous fat to build new fat cells. In a 4-month study of 13 type 2 diabetics, patients gained 3 kg (almost all fat), yet HbA1c dropped substantially and liver insulin sensitivity nearly doubled because scans showed a ~25% shift of fat out of visceral/organ depots and into subcutaneous storage. In a larger randomized trial, pioglitazone caused weight gain while resolving liver inflammation outright in ~50% of patients.
• Genetic and Pharmacological Evidence for Liver Fat: A Mendelian randomization study of ~30,000 scans showed that gene variants causing higher liver fat directly increase type 2 diabetes risk by ~25% (smaller than observational numbers because real-world fatty liver travels with confounders like inactivity, alcohol use, and socioeconomic status). Meanwhile, normal-weight type 2 diabetics can achieve remission by losing ~6% of their body weight, and exercise pulls fat out of the liver without changing scale weight. In drug development, retatrutide drops liver fat by >80% on scans, though Dr. Feigenbaum cautions there is not yet a single liver biopsy study backing it.
• Hidden Fatty Liver and Fibrosis Progression: Normal weight and normal liver enzymes (ALT) do not rule out liver disease. In a study of 100 type 2 diabetics with completely normal liver enzymes, 75% had fatty liver on scans (including ~66% of the non-obese patients), and biopsies of the worst scans showed >50% had active inflammation and damage (steatohepatitis). A 20-year Swedish cohort study matching 646 biopsy-confirmed fatty liver patients 1:10 to controls found 12% developed severe liver disease (cirrhosis, failure, or cancer) vs. 2% of controls (>5x risk). Risk is driven entirely by scarring (fibrosis): no scarring carries ~2x risk, existing cirrhosis carries ~100x risk, and adding steatohepatitis (inflammation) to the model adds zero predictive value once scarring stage is known.
• Evolution of Body Fat Metrics and the 2025 Lancet Commission: Body metrics evolved from Adolphe Quetelet's 1832 weight / height² formula for the "average man," to 1930s insurance mortality tables, to Ancel Keys naming Quetelet's formula BMI in 1972, to the 1998 NIH addition of waist circumference, and the 2013 elliptical Body Roundness Index (BRI). While a BMI >30 is ~95% accurate at ruling in excess fat, it misses ~50% of people who actually have excess fat (a meta-analysis of 31 papers and 300,000 adults showed waist circumference improves accuracy by ~3 percentage points, and waist-to-height ratio by 4–5 points). Consequently, the 2025 Lancet Commission (58 commissioners) declared BMI should only be used for population screening; individual diagnosis requires waist or direct fat measurement (unless BMI >40) and splits obesity into Pre-clinical obesity (excess fat with normal organ function) and Clinical obesity (organ dysfunction from fat tissue).

Quotes

• At 1:05 - "None of the numbers got better. 10 kilos of fat were taken out of the human, and the disease didn't notice." - Explaining the 2004 Klein liposuction study, demonstrating that physically sucking out subcutaneous fat does not fix metabolic disease.
• At 6:08 - "Now, your blood is carrying fuel, and fuel in your blood is not where fuel is supposed to live. Blood is the delivery truck, it's not the warehouse." - Clarifying basic post-meal fuel metabolism and the role of insulin in clearing the bloodstream.
• At 7:49 - "So, insulin resistance stays invisible for years. It doesn't show up as high blood sugar. It shows up as a normal blood sugar bought at an enormous price, and you only find out what that price was when the pancreas finally can't keep up." - Describing how pancreatic hypersecretion masks underlying insulin resistance for 10 to 15 years before a type 2 diabetes diagnosis.
• At 11:17 - "Doctors have a word for fat when it ends up in those places. They call it ectopic fat, and ectopic just means it's in the wrong place. That's all, fat in a room that was never built to hold it." - Defining ectopic fat as fuel that overflows into the liver, muscle, pancreas, kidneys, and heart once subcutaneous storage is full.
• At 12:41 - "Dinner only accounted for about 15% of the fat found in the liver. Some of it, about a quarter, the liver had built itself out of carbohydrate. But the biggest share, close to 60%, came out of the person's own fat tissue. It wasn't delivered, it leaked." - Detailing the 2005 chemical-tagging biopsy study that proved fatty liver is primarily caused by leaking, insulin-resistant fat cells.
• At 29:06 - "There's a class of diabetes drugs that does something that sounds like a mistake. It makes people gain weight, and it makes them healthier, and it does the second thing by causing the first." - Introducing pioglitazone, which proves the Personal Fat Threshold model by expanding subcutaneous fat storage to pull toxic fat out of the liver.
• At 37:19 - "So, normal ALT doesn't clear you, and neither does a normal body weight. Our 41-year-old patient was cleared twice by two things that can't clear anybody." - Highlighting a clinical case of a lean weightlifter (BMI 24, HbA1c 7.1%, ALT 48) to show why clinicians miss fatty liver in non-obese patients.
• At 47:32 - "That's the disease. The overflow is the disease we call obesity. It's the point where somebody's storage runs out and starts spilling into organs that were never built to hold it." - Summarizing the overarching thesis of the episode regarding how clinical obesity and metabolic dysfunction should be understood.

Takeaways

• Track your Waist-to-Height Ratio instead of relying on BMI alone: Because BMI misses ~50% of individuals carrying excess body fat, measure your waist circumference and divide it by your height, aiming to keep your ratio above 0.4 and under 0.5.
• Use the TyG Index to screen for hidden insulin resistance: Calculate your Triglyceride-Glucose (TyG) index using standard fasting triglycerides and fasting glucose rather than the Triglyceride-to-HDL ratio (which is only ~2/3 accurate and fails in Black patients who often do not develop high triglycerides when insulin resistant). Note that while TyG has an AUC of 0.6 to 0.85 across 4 inconsistent studies and cannot diagnose disease alone, a high score signals the need to look harder for metabolic dysfunction.
• Screen lean diabetics for non-Type 2 diabetes: If you or a patient are diagnosed with type 2 diabetes at a normal body weight, test to rule out adult-onset Type 1 (autoimmune) diabetes and MODY (Maturity-Onset Diabetes of the Young, caused by a single inherited gene), as research shows 1 in 6 lean patients diagnosed with Type 2 actually have a different form of diabetes.
• Evaluate liver scarring using age-appropriate FIB-4 and Elastography: Do not assume normal ALT levels or a normal BMI rule out fatty liver; instead, calculate a FIB-4 score (using age, AST, ALT, and platelets) to estimate liver scarring only if you are between ages 35 and 65 (under 35 it is barely better than a coin flip; over 65 it causes high false positives), and follow up with ultrasound elastography to measure liver stiffness and detect moderate-to-severe fibrosis without a biopsy.